 So the monumental one clinical trial is a early phase clinical trial phase one phase two and it did examine the efficacy and the safety, but also the dosing regimen of a completely new drug a anti-GPRC5D antibody by specific antibody and So we were looking at how high can we dose it? How should we give it to patients and what's the most effective dose that there is and what are the side effects of this drug? Because it's a completely new Antigen that we are targeting on myeloma cells So the efficacy results demonstrated that in a highly refractory population So there were patients already receiving produce so many heritages immunomilatory drugs like larylidomide, pulmalidomide and also Darytumab or another NTC 38 antibody the response rates were above 70% So in the end we had two cohorts one cohort is a bit lower dose dosing every week and the other dose is still point eight in the cramps per kilograms and that's dosing every two weeks So they were a bit different 71 or 73 something percent above 70% Response rate and also the duration of response was a bit different between the two cohorts, but it was around a year But it's very important in the biospecific antibodies. There's no use of dexamethasone And then you realize how much effect that drug has on patients So most patients felt fine, but they had a very specific side effect and that is that they had dyscusia It means that your taste is altering and you You're not liking if you're not tasting food You're eating less food, but also a dry mouth or sometimes some pain in the mouth So people lost weight. So that was a problem. Another side effect was that their nails are changing So their nails are not strong anymore. They are yeah a bit How do you call it? They are you're losing your not losing your nails, but they're no, they're not strong anymore And also your skin gets very dry And we had some patients also have a side effect that they every time they are injected with the drug They have a red bum for three days after it. So it's not big problem that they are reacting to the drug even after several cycles And we haven't seen that before in this type of Inu therapy, but we do know this of course from classical chemo therapy that you don't eat that your taste is different Or that you have nail problems or skin problems So these are the side effects that that we see they are there all the time because it's a therapy that you have to continue and And we are looking as To diminish those side effects of course with some additional care for your skin over your mouth But also with those reducing or dose frequency reducing So instead of every two weeks if you are nicely in remission then we dose That we give the same dose every four weeks for example, and then we see we do see that there is a decrease in in these side effects So in that sense, I do believe we have step-up dosing like we have it every by specific antibody so we have two or three step-up doses and then we go to the full dose and that's still all in hospital because you can have a cytokine release syndrome after every step of those or after the First full dose and you can have it twice for example you can have it on the second step up and the full dose So we do that in the hospital and I think afterwards what I like is of course the bi-weekly schedule so every two weeks as a one injection every two weeks and I like to dose reduce when you are in remission in a CR that we go to every four weeks, but that's not the official One yet. I think the official one. It's not a registered drug So we don't know what's the official one, but I think it will be one one injection every two weeks So not in a working mechanism. That's the same for all by specifics, but it's unique because of the antigen that it's targeting So GPAR C5D is highly expressed on myeloma cells. It is also expressed on normal plasma cells And it's expressed a bit on the skin and your taste organs. So that's why we see these strange side effects But that's a very low rate What we don't see as much as with other Bi-specific antibodies targeting BCMA is that we don't see that many infections So that's a problem can be a problem with the other with the Teclistamab for example And we don't see that with the GPAR C5D Talkatoma targeting by a specific antibody So this is a unique antigen and that's good because we need after we had CD38 That's is that took some up or their tumor map. We had BCMA now We have GPAR C5D and we also have other antigens and that's good because then you can sequence Therapies again for patients or combine, but we can we can target your myeloma on a different antigen perhaps Which is still highly expressed and so that's good So it means that and not at the moment because it's never it's only available now in clinical trials It's not registered in any country, but what it means. It's a new therapeutic option So that's always good news. That's still the problem with myeloma If you can't be sure you need new therapies which work on a different way on a different antigen So that's what it means to hope again